Herbalife 배당 및 자사주 매입
배당 기준 점검 0/6
Herbalife 배당금을 지급한 기록이 없습니다.
핵심 정보
0%
배당 수익률
0.5%
자사주 매입 수익률
| 총 주주 수익률 | 0.5% |
| 미래 배당 수익률 | 0% |
| 배당 성장률 | n/a |
| 다음 배당 지급일 | n/a |
| 배당락일 | n/a |
| 주당 배당금 | n/a |
| 배당 성향 | 0% |
최근 배당 및 자사주 매입 업데이트
Recent updates
HLF: Refinancing And Margin Improvement Will Support Turnaround Despite Weak EBITDA Guidance
Narrative update on Herbalife Analysts have raised their price target on Herbalife by $2, citing research that points to updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish analysts raising their price target by US$2 are signaling a more constructive view on how Herbalife’s valuation lines up with its fundamentals.Investors Can Find Comfort In Herbalife's (NYSE:HLF) Earnings Quality
Investors were disappointed with the weak earnings posted by Herbalife Ltd. ( NYSE:HLF ). However, our analysis...Herbalife: The Stock Wall Street Loves To Hate Is Making A Comeback
Summary Herbalife is undergoing a significant transformation, shifting from its traditional multi-level marketing model to a modern health and wellness brand. HLF is leveraging biomarker-driven personalization, direct digital health engagement, and strategic acquisitions like Bioniq and Pro2col to diversify its offerings. Recent debt refinancing and ongoing reductions have improved HLF's financial profile, with debt falling from ~$3.0B in 2021 to ~$2.18B in 2025. Wall Street has largely discounted HLF's transformation, overlooking its established brand, cash flow, and loyal customer base supporting its strategic pivot. Read the full article on Seeking AlphaHLF: Mixed 2026 Guidance And Execution Outlook Will Shape Turnaround Prospects
Herbalife's analyst price target has been revised higher to $17.50 from $16.50, with analysts pointing to updated fair value assumptions and recent target increases at firms such as Citi, BofA and Mizuho following Q4 results and 2026 guidance. Analyst Commentary Recent research updates show a mix of optimism and caution around Herbalife, with price targets moving in different directions as analysts react to Q4 results, 2026 guidance and updated assumptions around execution and valuation.HLF: 2026 Guidance And Margin Recovery Will Drive Turnaround Momentum
Analysts lifted their price targets for Herbalife by as much as $4, with some pointing to Q4 results that were largely in line, fresh 2026 guidance, and what they view as stronger recent momentum as key factors behind the adjustment. Analyst Commentary Bullish analysts are highlighting recent price target increases on Herbalife as a sign of improving confidence in the story, especially after Q4 results that were described as largely in line and supported by new 2026 guidance.HLF: Turnaround Momentum And Q1 2026 Outlook Will Support Margin Recovery
Herbalife's updated analyst price target has moved from $14.00 to $16.50 as analysts factor in recent target increases, slightly higher projected revenue growth and margins, and a modestly lower discount rate, alongside updated views on valuation multiples. Analyst Commentary Recent research views on Herbalife show a mix of optimism about a potential turnaround and caution about the broader sector and the company’s fundamentals.HLF: 2026 Turnaround Ambitions Will Face Ongoing Competitive And Fundamental Pressures
Herbalife's analyst price target has shifted toward $9.00, with recent research citing Q4 results viewed as solid by some firms, new 2026 guidance, and mixed views on valuation and competitive pressures. Some analysts also commented that regulatory concerns in the U.S. are considered resolved and the business model more sustainable.HLF: 2026 Turnaround Hopes Will Confront Persistent Competitive And Fundamental Risks
The analyst price target for Herbalife has been raised by $1 to $9. Analysts point to largely in line Q4 results, new 2026 guidance, and a mix of Buy, Neutral, and Underperform views that reflect both perceived momentum and ongoing concerns around competition, fundamentals, and valuation.HLF: Turnaround Will Be Driven By 2026 Guidance And Margin Recovery
Narrative Update: Herbalife The updated analyst fair value estimate for Herbalife has moved from $11 to $25, a shift analysts link to refreshed price targets in the $9 to $21 range, stronger Q4 commentary, improved margin assumptions, and a lower discount rate despite mixed views on long term growth and valuation risks. Analyst Commentary Recent Street research on Herbalife reflects a mix of views, but several bullish analysts have been willing to raise price targets or upgrade their stance following recent updates from the company.HLF: Turnaround Hopes Under New Leadership Will Confront Compressed Sector Multiples
Narrative Update: Herbalife Analyst Price Target Move The blended analyst price target for Herbalife has moved higher, with recent increases such as Mizuho's lift to $13 and Maxim's initiation at $20. Analysts point to an ongoing turnaround, progress under new leadership, and a healthier long term profile for Herbalife's business model, while also noting continuing concerns about competition and broader macro uncertainty.HLF: Recovery Story Under New Leadership Will Face Compressed Sector Multiples
Narrative Update on Herbalife The analyst price target for Herbalife has been revised higher to reflect an updated fair value of $8.00, a lower discount rate of 10.02%, and adjustments to revenue growth, profit margin, and future P/E assumptions, as analysts factor in recent target hikes, Buy initiations, and views of a continuing recovery path under new leadership. Analyst Commentary Recent Street research on Herbalife reflects a mix of optimism about a potential recovery and caution around execution and valuation risks.Herbalife Ltd. (NYSE:HLF) Shares Fly 27% But Investors Aren't Buying For Growth
Herbalife Ltd. ( NYSE:HLF ) shares have continued their recent momentum with a 27% gain in the last month alone. The...HLF: Turnaround And Margin Recovery Under New Leadership Will Face Valuation Constraints
The analyst price target on Herbalife in our model has moved from US$12 to US$14, as analysts point to a recovery path supported by a healthier profit margin outlook, a slightly lower discount rate, and recent research highlighting ongoing business model improvements despite tempered revenue growth expectations and cautious sector valuations. Analyst Commentary Recent research on Herbalife reflects a mix of optimism about the company’s turnaround efforts and caution about broader sector and macro headwinds.HLF: Recovery Path Under New Leadership Will Likely Deliver Disappointing Multiple Expansion
Analysts have modestly raised their fair value estimate for Herbalife from approximately $9.67 to $12.00 per share, citing a lower perceived risk profile, steady growth and margin assumptions, and a more constructive view on future earnings multiples as fundamentals continue on a recovery path under new leadership. Analyst Commentary Analyst sentiment around Herbalife is gradually improving as execution under new leadership gains traction and forward growth expectations firm up, though views on the pace and durability of the recovery remain mixed.HLF: Recovery Path Under New Leadership Will Likely Prove Overpriced
Analysts have modestly raised their price target on Herbalife to $11 from $10, citing a gradually lower perceived risk profile, steady long term growth and margin assumptions, and growing confidence that the company is on a recovery path under new leadership, with a potential return to volume growth by fiscal 2026. Analyst Commentary Bullish analysts point to the recent rating upgrade and price target increase as evidence that sentiment around Herbalife is gradually improving, with expectations that operational execution will support a more favorable risk and reward profile over the next several years.HLF: Uncertainty Around CEO Transition Will Challenge Near-Term Momentum
Herbalife’s analyst price target has been raised to $11 from $10, as analysts point to recovering fundamentals and the company’s strategic leadership changes as promising signs for future growth. Analyst Commentary Analysts have recently weighed in on Herbalife, offering a mix of optimism about its improving fundamentals and some caution about ongoing risks.We Think That There Are Some Issues For Herbalife (NYSE:HLF) Beyond Its Promising Earnings
The market for Herbalife Ltd.'s ( NYSE:HLF ) stock was strong after it released a healthy earnings report last week...The Market Doesn't Like What It Sees From Herbalife Ltd.'s (NYSE:HLF) Earnings Yet
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...At US$8.75, Is Herbalife Ltd. (NYSE:HLF) Worth Looking At Closely?
Herbalife Ltd. ( NYSE:HLF ), might not be a large cap stock, but it saw a decent share price growth of 11% on the NYSE...A Look At The Intrinsic Value Of Herbalife Ltd. (NYSE:HLF)
Key Insights The projected fair value for Herbalife is US$9.20 based on 2 Stage Free Cash Flow to Equity Herbalife's...There's No Escaping Herbalife Ltd.'s (NYSE:HLF) Muted Earnings Despite A 26% Share Price Rise
Those holding Herbalife Ltd. ( NYSE:HLF ) shares would be relieved that the share price has rebounded 26% in the last...Herbalife (NYSE:HLF) Hasn't Managed To Accelerate Its Returns
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Herbalife's (NYSE:HLF) Earnings Offer More Than Meets The Eye
Herbalife Ltd.'s ( NYSE:HLF ) solid earnings announcement recently didn't do much to the stock price. We did some...Herbalife Ltd.'s (NYSE:HLF) Share Price Boosted 63% But Its Business Prospects Need A Lift Too
Herbalife Ltd. ( NYSE:HLF ) shares have had a really impressive month, gaining 63% after a shaky period beforehand. But...Herbalife: The Battleground Stock Is Showing Some Turnaround Potential
Summary Herbalife still operates in 95 countries using a direct selling and MLM model with six million independent distributors. Currently, HLF is facing declining sales volumes, which have been partly offset by price increases. However, it remains uncertain how sustainable this is in the long run. Post-FTC settlement, I think HLF has “sanitized” its business model, even though it has indeed made it more challenging to grow its MLM business. The good news is its focus. They have a mixed regional performance, in particular with China struggling while Asia Pacific stabilizes. Additionally, its recruitment and sales leaders numbers have been encouraging in Q4 and 2024. Based on EV/EBITDA metrics, HLF is undeniably still priced at a steep discount. However, at this point, I believe the risk-reward equation is more favorable for the bulls. Hence, I rate it a speculative “Buy” for the short term. Read the full article on Seeking AlphaIs It Time To Consider Buying Herbalife Ltd. (NYSE:HLF)?
While Herbalife Ltd. ( NYSE:HLF ) might not have the largest market cap around , it saw a double-digit share price rise...Returns At Herbalife (NYSE:HLF) Appear To Be Weighed Down
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...Herbalife: Down In The Dumps, But Maybe Worth Exploring
Summary Herbalife (HLF) which offers health and wellness products across the globe has underperformed other small-caps and consumer staple stocks, while witnessing almost a 50% contraction in price over the past year. The new Chief Strategy Officer has helped revive new distributor growth after years of decline, but sales growth remains stagnant, and the outlook on the topline doesn't look too alluring. While the topline is not at full tilt, HLF's restructuring efforts are leading to a great deal of savings ($130m of aggregate savings through 2025) resulting in decent EBITDA growth. The stock is attractively priced at 4x EBITDA and an FCF yield of 27%. HLF is yet to show signs of bottom formation, although the risk-reward equation within its long-term descending channel looks favorable. Read the full article on Seeking AlphaInvestors Still Aren't Entirely Convinced By Herbalife Ltd.'s (NYSE:HLF) Earnings Despite 27% Price Jump
Herbalife Ltd. ( NYSE:HLF ) shares have had a really impressive month, gaining 27% after a shaky period beforehand. Not...We Think You Can Look Beyond Herbalife's (NYSE:HLF) Lackluster Earnings
Herbalife Ltd.'s ( NYSE:HLF ) stock was strong despite it releasing a soft earnings report last week. However, we think...Herbalife: A Top Short Squeeze Idea, Turning Higher In Price
Summary Herbalife is trading near a 20-year low valuation in October 2024. Earnings have beaten expectations for 3 consecutive quarters and are projected to grow by 20% annually in 2025-26. A large short interest position may be stuck, meaning any covering (buying shares) will push the share price straight up. Something of a price breakout has appeared on the daily chart pattern over the past week. Read the full article on Seeking AlphaWhat Does Herbalife Ltd.'s (NYSE:HLF) Share Price Indicate?
Herbalife Ltd. ( NYSE:HLF ), is not the largest company out there, but it saw a decent share price growth of 12% on the...지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: 과거에 HLF 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.
배당금 증가: HLF 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.
배당 수익률 vs 시장
| Herbalife 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (HLF) | 0% |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.1% |
| 업계 평균 (Personal Products) | 3.1% |
| 분석가 예측 (HLF) (최대 3년) | 0% |
주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 HLF 의 배당 수익률을 평가할 수 없습니다.
고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 HLF 의 배당 수익률을 평가할 수 없습니다.
주주 대상 이익 배당
수익 보장: HLF US 시장에서 주목할만한 배당금을 지급하지 않습니다.
주주 현금 배당
현금 흐름 범위: HLF 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/14 18:26 |
| 종가 | 2026/06/12 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Herbalife Ltd.는 15명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| John Staszak | Argus Research Company |
| Meredith Adler | Barclays |
| Brian Wang | Barclays |